These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20068401)

  • 21. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugates: Intellectual property considerations.
    Storz U
    MAbs; 2015; 7(6):989-1009. PubMed ID: 26292154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies].
    Biot J; Fasano C; Dos Santos C
    Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
    Wolff ME
    J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How market smarts can protect property rights.
    Anand B; Galetovic A
    Harv Bus Rev; 2004 Dec; 82(12):72-9, 148. PubMed ID: 15605567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioinformatics: the role and limitations of patents.
    Welch TJ
    Drug Discov Today; 2002 Jun; 7(11):S77-82. PubMed ID: 12047884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.
    Bian H; McCourt C
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25573772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
    Shah S; Silva MA; Malloy MJ
    Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880
    [No Abstract]   [Full Text] [Related]  

  • 31. [The Brazilian market for monoclonal antibodies used in cancer treatment].
    Vidal TJ; Figueiredo TA; Pepe VLE
    Cad Saude Publica; 2018 Nov; 34(12):e00010918. PubMed ID: 30517310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can next-generation antibodies offset biosimilar competition?
    Mullard A
    Nat Rev Drug Discov; 2012 Jun; 11(6):426-8. PubMed ID: 22653202
    [No Abstract]   [Full Text] [Related]  

  • 33. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.
    Kesselheim AS
    AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Legal Test for the Pharmaceutical Company Practice of "Product Hopping".
    Klusty T
    AMA J Ethics; 2015 Aug; 17(8):760-2. PubMed ID: 26270876
    [No Abstract]   [Full Text] [Related]  

  • 37. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Increasingly Human and Profitable Monoclonal Antibody Market.
    Grilo AL; Mantalaris A
    Trends Biotechnol; 2019 Jan; 37(1):9-16. PubMed ID: 29945725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 40. Ethical reasons for narrowing the scope of biotech patents.
    Andreassen T
    Med Health Care Philos; 2015 Nov; 18(4):463-73. PubMed ID: 25968142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.